KRON Kronos Bio Inc.

Biotech Analyst Ratings

Latest News

1. 17 May 2022 Kronos Bio Announces Participation in H.C. Wainwright Global Investment Conference

   SAN MATEO, Calif. and CAMBRIDGE, Mass., May 17, 2022 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (NASDAQ:KRON), a company dedicated to transforming the lives of those affected by cancer and other serious diseases, today announced participation in the H.C. Wainwright Global Investment Conference. An on-demand webcast of the presentation will be available on Tuesday, May 24, 2022, at 7 a.m. ET.
   

   The webcast will be available on the Investors and Media section of the Kronos Bio website at www.kronosbio.com. A replay of the webcast will be archived and available for 30 days following the event.

   About Kronos Bio, Inc.
   Kronos Bio is a clinical-stage biopharmaceutical company dedicated to discovering and developing therapies that seek to transform the lives…

   View Full Article
2. 12 May 2022 Kronos Bio's Investigational SYK Inhibitors Entospletinib and Lanraplenib to be Featured in Four Poster Presentations at EHA2022 Congress

   Posters include preclinical data on SYK inhibition in combination with targeted agents and demonstrate preclinical anti-tumor activity in acute myeloid leukemia (AML)
   

   Additional presentations detail trial designs for Kronos Bio's Phase 3 registrational study of entospletinib and Phase 1b/2 lanraplenib trial in genetically defined AML

   SAN MATEO, Calif. and CAMBRIDGE, Mass., May 12, 2022 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (NASDAQ:KRON), a company dedicated to transforming the lives of those affected by cancer and other serious diseases, today announced that its two novel investigational spleen tyrosine kinase (SYK) inhibitors, entospletinib and lanraplenib, will be featured in poster presentations at the European Hematology Association (EHA…

   View Full Article
3. 04 May 2022 Kronos Bio Reports Recent Business Progress and First-Quarter 2022 Financial Results

   Preclinical data on CDK9 inhibitor KB-0742 presented at AACR add to evidence of potential activity in MYC-amplified and transcriptionally addicted tumors; company plans to announce RP2D and additional Phase 1 data in Q4 2022

   $315.4 million in cash, cash equivalents and investments as of March 31, 2022, providing expected runway into the second half of 2024

   SAN MATEO, Calif. and CAMBRIDGE, Mass., May 04, 2022 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (NASDAQ:KRON), a company dedicated to transforming the lives of those affected by cancer and other serious diseases, today reported recent business progress and first quarter 2022 financial results.

   "We continued to advance our three clinical programs this quarter and, in addition, presented preclinical…

   View Full Article
4. 08 April 2022 Kronos Bio Presents Preclinical Data on Oral CDK9 Inhibitor KB-0742, Providing Additional Evidence of Potential Efficacy in MYC-Amplified and Transcriptionally Addicted Tumors at AACR

   Preclinical data featured in three posters show potential of KB-0742 in triple-negative breast, lung and ovarian cancers, as well as lymphoma and rare, soft-tissue cancers, including sarcoma and chordoma

   Company will also present data demonstrating the potential of its new liquid biopsy assay platform to help evaluate patient response to KB-0742 in the ongoing Phase 1/2 study

   Kronos Bio continues to enroll patients in Phase 1/2 clinical trial, with additional data anticipated in Q4 2022

   SAN MATEO, Calif. and CAMBRIDGE, Mass., April 08, 2022 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (NASDAQ:KRON), a company dedicated to transforming the lives of those affected by cancer and other serious diseases, today shared preclinical data on its internally…

   View Full Article
5. 08 March 2022 Kronos Bio's Investigational CDK9 Inhibitor KB-0742 to be Featured in Four Preclinical Poster Presentations at American Association for Cancer Research Annual Meeting 2022

   Data include results from preclinical studies of KB-0742 in MYC-amplified cancers, including small-cell lung, triple-negative breast and ovarian, as well as lymphoma
   Posters also feature data from preclinical chordoma and sarcoma models
   KB-0742 is being evaluated in an ongoing Phase 1/2 trial

   SAN MATEO, Calif. and CAMBRIDGE, Mass., March 08, 2022 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (NASDAQ:KRON), a company dedicated to transforming the lives of those affected by cancer and other serious diseases, today announced that it will present preclinical data on its internally discovered, highly selective, oral cyclin dependent kinase 9 (CDK9) inhibitor, KB-0742, in four poster presentations at the American Association for Cancer Research (AACR) Annual…

   View Full Article